In early December, the US Food and Drug Administration granted accelerated approval to adagrasib, a mutant-selective inhibitor of the Kirsten rat sarcoma viral homolog (KRAS), for the treatment of metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation after one prior therapy.1 Adagrasib now joins sotorasib,2 which received accelerated approval in May, 2021 for the same indication. This evidence concerns the gene KRAS and non-small cell lung carcinoma.